在BRCA突变敏感卵巢癌复发中的olaparib剂量减少:现实世界的数据
Serena Maria Boccia1, Matteo Bruno1, Camilla Culcasi2
1Department of Woman and Child and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
概括
减少olaparib (一种PARP抑制剂) 的剂量并没有对复发性卵巢癌患者的生存结果产生负面影响. 这表明调整olaparib剂量是管理治疗相关副作用的安全策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥拉巴里布对BRCA突变卵巢癌有效.
- 血液毒性经常导致olaparib剂量调整.
- 关于剂量降低影响的现实数据有限.
研究的目的:
- 为了研究复发性卵巢癌患者的生存结果,接受olaparib剂量减少.
- 为了在不同的olaparib剂量水平上比较无进展生存期 (PFS) 和整体生存期 (OS).
主要方法:
- 87名BRCA突变卵巢癌患者 (2019-2022) 的回顾性分析.
- 根据olaparib剂量分组的患者:没有减少 (600毫克),1级 (500毫克),2级 (400毫克).
- 主要终点:PFS和OS;次要终点:减少率和安全性.
主要成果:
- 45%的患者需要降低剂量.
- 平均PFS:27个月 (没有减少),28个月 (一级),32个月 (二级).
- 平均生存期:44个月 (没有减少),52个月 (一级),43个月 (二级). 在标准剂量组中,≥3级的副作用很少发生;疲劳和恶心很常见.
结论:
- 减少olaparib剂量并没有影响该队列的瘤结果.
- 降低剂量是一种可行的方法来管理olaparib相关的不良事件.
- 需要在更大的研究中进一步验证.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


